Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVRx, Inc. stock logo
CVRX
CVRx
$2.72
-5.9%		$3.64
$2.20
▼
$11.30
$76.99M0.76571,368 shs481,615 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$71.94
-0.6%		$64.07
$23.47
▼
$77.00
$231.95M0.0675,954 shs96,359 shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$5.00
+1.4%		$4.89
$2.20
▼
$7.95
$303.56M0.44256,784 shs2.59 million shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
-1.7%		$4.50
$1.17
▼
$7.08
$298.51M1.4221,997 shs317,965 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVRx, Inc. stock logo
CVRX
CVRx
-5.88%-9.93%-13.65%-48.19%-63.49%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-0.65%+0.13%+7.60%+10.15%+112.15%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
+1.42%+1.42%-2.15%+14.42%+2.67%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-1.74%-1.10%+3.20%+1.35%-33.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVRx, Inc. stock logo
CVRX
CVRx
$2.72
-5.9%		$3.64
$2.20
▼
$11.30
$76.99M0.76571,368 shs481,615 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$71.94
-0.6%		$64.07
$23.47
▼
$77.00
$231.95M0.0675,954 shs96,359 shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$5.00
+1.4%		$4.89
$2.20
▼
$7.95
$303.56M0.44256,784 shs2.59 million shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
-1.7%		$4.50
$1.17
▼
$7.08
$298.51M1.4221,997 shs317,965 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVRx, Inc. stock logo
CVRX
CVRx
-5.88%-9.93%-13.65%-48.19%-63.49%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-0.65%+0.13%+7.60%+10.15%+112.15%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
+1.42%+1.42%-2.15%+14.42%+2.67%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-1.74%-1.10%+3.20%+1.35%-33.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVRx, Inc. stock logo
CVRX
CVRx
2.17
Hold$4.3058.09% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
3.00
Buy$74.002.86% Upside
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.40
Hold$10.20104.00% Upside
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
1.86
Reduce$5.1714.63% Upside

Current Analyst Ratings Breakdown

Latest CVRX, TLSI, TMCI, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$12.00
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$12.00
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$11.00 ➝ $12.00
9/22/2026
CVRx, Inc. stock logo
CVRX
CVRx
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
9/21/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
9/15/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/11/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$70.00 ➝ $74.00
9/10/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/9/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$11.00
9/9/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$11.00
9/4/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVRx, Inc. stock logo
CVRX
CVRx
$56.65M1.28N/AN/A$1.50 per share1.81
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$77.55M2.97$3.88 per share18.55$14.92 per share4.82
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$45.15M6.82N/AN/A($0.68) per share-7.35
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$212.69M1.38N/AN/A$1.37 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVRx, Inc. stock logo
CVRX
CVRx
-$53.31M-$1.98N/AN/AN/A-84.93%-152.35%-50.93%11/4/2026 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$13.66M$4.1317.4221.41N/A17.62%25.13%16.02%10/29/2026 (Estimated)
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$39.23M-$1.30N/AN/AN/A-62.59%N/A-64.47%11/12/2026 (Estimated)
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$59M-$0.93N/AN/AN/A-28.99%-71.37%-30.49%11/5/2026 (Estimated)

Latest CVRX, TLSI, TMCI, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q4 2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.67$0.87+$0.20$0.87$19.20 million$20.41 million
8/7/2026Q2 2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$0.2980-$0.24+$0.0580-$0.24$44.02 million$45.38 million
8/6/2026Q2 2026
CVRx, Inc. stock logo
CVRX
CVRx
-$0.5246-$0.53-$0.0054-$0.53$15.55 million$15.71 million
8/6/2026Q2 2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.1550-$0.16-$0.0050-$0.16$10.27 million$11.41 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/AN/AN/AN/AN/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVRx, Inc. stock logo
CVRX
CVRx
2.94
8.04
6.87
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.28
4.10
2.45
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
5.05
5.35
4.97
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
0.83
2.90
1.95

Institutional Ownership

CompanyInstitutional Ownership
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.58%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
84.08%

Insider Ownership

CompanyInsider Ownership
CVRx, Inc. stock logo
CVRX
CVRx
16.60%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
45.90%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
16.30%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
23.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVRx, Inc. stock logo
CVRX
CVRx
22326.64 million22.22 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2063.20 million1.73 millionNot Optionable
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
10261.58 million51.54 millionNot Optionable
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
45065.04 million49.80 millionOptionable

Recent News About These Companies

Critical Comparison: Treace Medical Concepts (NASDAQ:TMCI) versus TransMedics Group (NASDAQ:TMDX)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044522
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
September 22 at 10:51 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/treace-medical-tmci-reports-five-year-bunion-results-can-evidence-drive-adoption-1840580/
Analyzing LogicMark (OTCMKTS:LGMKD) and Treace Medical Concepts (NASDAQ:TMCI)
September 21 at 8:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037138
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure
September 18, 2026  |  marketscreener.comM
Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...
September 18, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69614222-treace-medical-concepts-inc-treace-announces-results-of-three-clinical-studies-including-the-milestone-5-year-align3d-study-demonstrating-sustained-399.htm
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting
September 17, 2026  |  quiverquant.comQ
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3364415/0/en/treace-announces-results-of-three-clinical-studies-including-the-milestone-5-year-align3d-study-demonstrating-sustained-positive-outcomes-of-the-lapiplasty-procedure.html
Treace Highlights Foot & Ankle Portfolio Updates At 2026 AOFAS Annual Meeting
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691340/treace-highlights-foot-ankle-portfolio-updates-at-2026-aofas-annual-meeting.aspx
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026
September 15, 2026  |  quiverquant.comQ
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362722/0/en/treace-highlights-product-innovations-and-clinical-data-across-its-expanding-foot-ankle-portfolio-at-the-2026-aofas-annual-meeting.html
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-treace-medical-concepts-inc-tmci-2026-09-06/
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-treace-medical-concepts-inc-nasdaq-tmci-given-consensus-recommendation-of-reduce-by-analysts-2026-09-05/
Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-431-million-stock-holdings-in-treace-medical-concepts-inc-tmci-2026-08-29/
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tmci-insider-buying-and-selling-2026-08-25/
Treace Medical Concepts Earnings Call Signals Cautious Rebound
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/treace-medical-concepts-earnings-call-signals-cautious-rebound?utm_source=marketbeat.com&utm_medium=referral
Treace Medical (TMCI) Q2 2026 Earnings Call Transcript
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-tmci-q2-2026-135838195.html
Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-concepts-inc-q2-211202340.html
Treace Medical Concepts: Q2 Earnings Snapshot
August 7, 2026  |  seattlepi.comS
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933135-treace-medical-concepts-inc-tmci-q2-2026-earnings-call-transcript
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970789/treace-medical-concepts-tmci-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970789
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341035/0/en/treace-medical-concepts-reports-second-quarter-2026-financial-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVRx stock logo

CVRx NASDAQ:CVRX

$2.72 -0.17 (-5.88%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$2.73 +0.01 (+0.37%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$71.94 -0.47 (-0.65%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$72.01 +0.07 (+0.10%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

TriSalus Life Sciences stock logo

TriSalus Life Sciences NASDAQ:TLSI

$5.00 +0.07 (+1.42%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$4.84 -0.17 (-3.30%)
As of 06:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Treace Medical Concepts stock logo

Treace Medical Concepts NASDAQ:TMCI

$4.51 -0.08 (-1.74%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$4.53 +0.02 (+0.44%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas